APP
GCVRZ

Avantax Planning Partners’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Avantax Planning Partners’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-525
Closed – – 1486
2018
Q3 		$0 Buy
+525
New +$281 ﹤0.01% 1481
2018
Q2 		– Sell
-525
Closed – – 1905
2018
Q1 		$0 Buy
+525
New +$211 ﹤0.01% 1913

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
NGA
New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return

Avantax Planning Partners's GCVRZ Position: Q4 2018 in Review

Avantax Planning Partners sold out of Sanofi Contingent Value Rights (GCVRZ) in Q4 2018, closing a stake of 525 shares.

Avantax Planning Partners first reported a position in GCVRZ in Q1 2018 and held it in 2 quarters. The position peaked at $0 in Q3 2018. 103 funds tracked by Wall St. Rank hold GCVRZ as of Q4 2018.

  • Avantax Planning Partners reported no remaining Sanofi Contingent Value Rights position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 525 Sanofi Contingent Value Rights shares in Q4 2018.
  • Avantax Planning Partners first reported a position in Sanofi Contingent Value Rights in Q1 2018 and held it in 2 quarters.
  • Avantax Planning Partners's Sanofi Contingent Value Rights position peaked at $0 in Q3 2018.
  • 103 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.